Valuation: TScan Therapeutics, Inc.

Market Cap 67.31M 59.04M 54.68M 50.31M 95.16M 6.44B 97.02M 652M 256M 3.16B 253M 247M 10.93B P/E 2026 *
-1.18x
P/E 2027 * -1.12x
Enterprise Value -31.56M -27.68M -25.63M -23.59M -44.61M -3.02B -45.48M -306M -120M -1.48B -118M -116M -5.12B EV / Sales 2026 *
-4.18x
EV / Sales 2027 * -0.95x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -
06-22 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
06-22 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
06-03 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
05-06 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-02 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
03-04 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
02-26 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
02-26 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
12-19 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
12-07 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
11-14 Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight MT
11-12 TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-12 TScan Therapeutics Q3 revenue jumps RE
1 day-5.50%
1 week-1.90%
Current month+5.09%
1 month+12.93%
3 months+0.98%
6 months-11.97%
Current year+3.00%
1 week 1.02
Extreme 1.0199
1.28
1 month 0.83
Extreme 0.8251
1.28
Current year 0.83
Extreme 0.8251
1.47
1 year 0.83
Extreme 0.8251
2.57
3 years 0.83
Extreme 0.8251
9.69
5 years 0.83
Extreme 0.8251
14.71
10 years 0.83
Extreme 0.8251
14.71
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Director of Finance/CFO 57 29/01/2024
Chief Tech/Sci/R&D Officer 50 08/04/2024
Director TitleAgeSince
Director/Board Member 68 23/03/2021
Director/Board Member 56 24/05/2023
Chairman 55 12/06/2024
Date Insider Type Main position Quantity % Market Cap.
05-20Free

Director

67,000 0.1200%
05-20
Baker Bros. Advisors LP
FreeCompany 134,000 0.2400%
05-20Free

Director

67,000 0.1200%
Change 5-day change 1-year change 3-year change Capi.($)
-5.50%-1.90%-43.09%-53.60% 67.31M
-2.48%-2.22%+55.85%+79.12% 53.54B
+0.47%-6.11%+56.46%+128.32% 54.18B
-5.60%-2.15%+11.16%+420.46% 23.66B
-1.55%-4.11%-20.21%-17.75% 22.78B
+2.36%+3.86%+42.80%-6.60% 19.54B
-0.33%-0.05%+38.16%-27.79% 17.82B
-2.72%-4.04%+187.08%+362.09% 16.01B
-1.15%-3.07%+45.33%+654.85% 15.37B
-0.81%+0.92%+24.92%+189.61% 14.09B
Average -1.74%-1.70%+39.85%+172.87% 23.71B
Weighted average by Cap. -1.32%-1.99%+48.13%+162.99%

Financials

2026 *2027 *
Net sales 7.56M 6.63M 6.14M 5.65M 10.68M 723M 10.89M 73.17M 28.7M 355M 28.38M 27.76M 1.23B 7.81M 6.85M 6.34M 5.84M 11.04M 747M 11.25M 75.59M 29.65M 367M 29.32M 28.68M 1.27B
Net income -115M -101M -93.48M -86.01M -163M -11.01B -166M -1.11B -437M -5.41B -432M -423M -18.68B -125M -109M -101M -93.3M -176M -11.95B -180M -1.21B -474M -5.87B -469M -458M -20.26B
Net Debt -98.87M -86.72M -80.32M -73.9M -140M -9.46B -142M -957M -375M -4.65B -371M -363M -16.05B -74.76M -65.57M -60.73M -55.88M -106M -7.16B -108M -724M -284M -3.51B -281M -275M -12.13B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
139
Date Price Change Volume
13/07/26 $1.030 -5.50% 1,152,419
10/07/26 $1.090 +2.83% 968,754
09/07/26 $1.060 -15.87% 1,266,274
08/07/26 $1.260 +17.76% 2,637,071
07/07/26 $1.070 +1.90% 606,643
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.030USD
Average target price
6.000USD
Spread / Average Target
+482.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock